Medications

Pembrolizumab slows MSI-H-dMMR metastatic CRC

(HealthDay)—For the first-line treatment of microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer, pembrolizumab is superior to chemotherapy for prolonging progression-free ...

Oncology & Cancer

New drug for metastatic colorectal cancer enters phase 3 trial

A new therapy for metastatic colorectal cancer that has been granted fast-track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.

Oncology & Cancer

Laparoscopic resection may be an option for CRC liver metastases

(HealthDay)—For patients with metastatic colorectal cancer who have resectable liver metastases, survival outcomes at five years do not differ significantly for treatment with laparoscopic versus open liver resection, according ...

page 1 from 9